Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Posted on 15 November 2018 | Posted by John Chapman | Posted in Videos, American Heart Association Scientific Sessions 2018

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).

Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.

Related videos

PlayVIDEO: Prof Stephen Nicholls Effect of alirocumab on MI types
VIDEO: Prof Stephen Nicholls Effect of alirocumab on MI types
PlayVIDEO: Novel PCSK9 therapeutics
VIDEO: Novel PCSK9 therapeutics
PlayVIDEO: BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids
VIDEO: BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids
PlayVIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points
VIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points

« Back to videos